Cardiff Oncology Inc. (CRDF)
Cardiff Oncology Inc. (CRDF) Stock Price, Analysis & Data
| Precio de compra | 0.67 |
| Capitalización de mercado | 70.74M |
| Ingresos (TTM) | 508K |
| Beneficio neto (TTM) | -40.08M |
| Beta | 1.44 |
| EPS (TTM) | -0.6 |
| Ratio PER (TTM) | n/a |
| Adelante PE | -1.55 |
| P/B (TTM) | 2.35 |
| P/S (TTM) | 139.25 |
| Earnings Date | Nov 12, 2026 |
| Precio de venta | 1.18 |
| Volumen | 77,019 |
| Volumen medio (20D) | 1,557,019 |
| Abierto | 0.90 |
| Anterior Cerrar | 0.90 |
| Rango del día | 0.90 - 0.93 |
| Rango de 52 semanas | 0.76 - 3.31 |
| analista | Buy |
| Precio objetivo | 4 (339.56%) |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de CRDF
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small...
Desempeño financiero
En 2025, los ingresos de Cardiff Oncology fueron 593K, una disminución de -13.18% en comparación con 683K del año anterior. Las ganancias fueron -45.85M, un aumento de 0.92%.
Estados financierosPronóstico del analista
Según las calificaciones de los analistas de 7, la calificación promedio de las acciones de CRDF es "Buy". El pronóstico del precio de las acciones a 12 meses es 4, que es Potencial alcista de 339.56% del último precio.
Previsiones bursátilesSorpresa de resultados
Los analistas proyectan ingresos de ... Actualizar
2 meses hace · Simply Wall St.
Cardiff Oncology And 2 Other Promising Penny Stocks For Your WatchlistOver the last 7 days, the U.S. market has dropped by 1.0%, yet it has risen by 23% over the past year, with earnings forecasted to grow annually by 17%. In such a fluctuating market, identifying stock...
